El interés en corto de NeuroOne Medical Tech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de NeuroOne Medical Tech. Los datos de interés en corto se actualizan cada dos semanas.

NeuroOne Medical Tech (NASDAQ:NMTC) Bolsa, Informe de interés en corto

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AMS, GES, NMTC, SLP y SGMO.

5 acciones en el foco este viernes: AMS, GES, NMTC, SLP y SGMO

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares are trading higher Tuesday after the company authorized a <a href="https://www.benzinga.com/pressreleases/25/04/n44674029/broadcom-inc-announces-10-billion-share-repurchase-authorization">$10 billion share repurchase program</a>.
What Happened: Broadcom&#8217;s board authorized a new buyback program, allowing the company to repurchase up to $10 billion of its common stock by Dec. 31, 2025.
Broadcom said the repurchase authorization reflects the board's confidence in the company's diversified businesses and strong cash flow generation.
"Today's announcement of a&nbsp;$10 billion&nbsp;share repurchase program reflects the Board's confidence in the strength of Broadcom's diversified semiconductor and infrastructure software product franchises," said&nbsp;Hock Tan, president and CEO of Broadcom.
"In particular, we are uniquely positioned in mission critical infrastructure software and enabling hyperscalers to drive innovation in generative AI into their expanding subscriber platforms."
Check This Out: <a href="https://www.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Marvell Plays AI Hardball: Divestiture Sparks 155% Upside, Says Analyst</a>
Broadcom noted that it may repurchase shares in the open market or make privately negotiated purchases under the new buyback program, but the company is not obligated to repurchase any shares.
AVGO Price Action: <a href="http://benzinga.com/quote/avgo" target="_blank" rel="noreferrer noopener">Broadcom shares</a> were up 8.38% at $166.77 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Ken Wolter/Shutterstock.

Buybacks

Movers

AVGO

Broadcom Shares Are Trading Higher Tuesday: What's Going On?

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) with a Buy and maintains $31 price target.

Price Target

Reiteration

Analyst Ratings

CLNN

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target

WIIM

NYXH

Nyxoah shares are trading higher after the company announced it's nearing FDA approval for Genio System. Additionally, HC Wainwright & Co. reiterated a Buy rating on the stock.

Needham analyst Ryan MacDonald reiterates DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) with a Buy and maintains $4 price target.

DCGO

Needham Reiterates Buy on DocGo, Maintains $4 Price Target

ASNS

Actelis Networks shares are trading higher after the company announced it received a new order to modernize Orange County's traffic infrastructure.

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is leveraging its Walmart+ membership program to drive growth and customer loyalty as escalating tariffs and global trade tensions threaten the U.S. economy. The subscription-based service, which launched nearly five years ago, has become a key driver of e-commerce growth and profitability for the retail giant.
What Happened: Nearly 50% of the spending on Walmart&#8217;s online platforms in the U.S. during the last fiscal year was from Walmart+ subscribers. These customers are said to shop twice as often and spend almost three times more than those without a subscription, <a href="https://www.cnbc.com/2025/04/08/walmart-memberships-boost-sales-amid-trump-tariffs-recession-fears.html?ref=biztoc.com">reported</a> CNBC.
Walmart&#8217;s Chief Growth Officer, Seth Dallaire, told the publication that the Walmart+ program is a &#8220;frequency driver&#8221; and has experienced an increase in spending per subscriber. The program also enables Walmart to maintain low grocery prices while investing in other areas to remain competitive.
The program has also contributed to Walmart's double-digit online sales growth for 11 consecutive quarters in the U.S., with a 20% increase in the latest quarter. 
Consumer Intelligence Research Partners estimates Walmart+ had 25 million members as of January, more than doubling from late 2022. While still far behind Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Prime membership base of 190 million U.S. subscribers, Walmart+ continues to gain traction, with membership penetration among Walmart.com shoppers rising from 23% three years ago to 43% today.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44673195/you-have-defeated-the-wealthiest-person-on-earth-says-bernie-sanders-as-he-applauds-wisconsins-choice-of-susan-crawford" target="_blank" rel="noreferrer noopener">&#8216;You Have Defeated The Wealthiest Person On Earth,&#8217; Says Bernie Sanders As He Applauds Wisconsin&#8217;s Choice Of Susan Crawford &#8211; Benzinga</a>
Why It Matters: The timing of Walmart+&#8217;s success is critical as President Donald Trump's expanded tariffs on goods from key manufacturing hubs like China and Vietnam are set to take effect this week. Analysts warn these tariffs could exacerbate economic uncertainty and strain consumer spending. However, Barclays retail analyst Seth Sigman notes that Walmart's position as the largest U.S. grocer provides stability. The retailer's ability to negotiate with suppliers and absorb costs may also mitigate tariff impacts.
Walmart plans to update investors on its membership program and alternative revenue streams, including advertising, at an event this week in Dallas. These initiatives are expected to help offset economic headwinds while solidifying customer loyalty and profitability in a challenging retail landscape.
Nevertheless, the membership program is likely to offer strength to Walmart and ensure its growth amid the tariff woes. Besides, the retail giant <a href="https://www.benzinga.com/media/25/04/44609843/walmart-pressures-chinese-suppliers-to-cut-prices-amid-new-tariff-battle">has been pressuring </a>Chinese suppliers to cut prices across product categories by up to 10% for each round of tariffs. This strategy is part of Walmart&#8217;s efforts to shift the burden of tariffs onto the suppliers. The negotiations are expected to intensify following Trump&#8217;s announcement of new reciprocal tariffs against major U.S. trading partners.
Seth Sigman, a retail analyst at Barclays, stated that revenue sources like memberships have boosted Walmart&#8217;s profitability and helped it retain more loyal, long-term customers.
Walmart holds a momentum rating of 91.57% and a growth rating of 54.91%, according to&nbsp;<a href="https://www.benzinga.com/quote/WMT" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Walmart stock has fallen 4.5% over the past month. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/25/04/44660007/mark-cuban-says-between-free-trade-elon-musk-and-full-tariff-trump-it-is-the-president-who-will-win-as-st" target="_blank" rel="noreferrer noopener">Mark Cuban Says Between &#8216;Free Trade&#8217; Elon Musk And &#8216;Full Tariff&#8217; Trump, It Is The President Who Will Win As Stocks Futures Tank</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AMZN

Walmart May Have An Ace Up Its Sleeve As Trump Tariffs And Slowdown Threaten Retail

Onconetix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares are trading higher by 33.6% to around 9 cents during Tuesday&#8217;s session after the company signed a <a href="https://www.benzinga.com/pressreleases/25/04/g44683189/onconetix-signs-letter-of-intent-for-potential-business-combination-with-ocuvex-therapeutics-inc">non-binding letter of intent</a> to potentially merge with privately held Ocuvex Therapeutics.
What To Know: The proposed deal would shift Onconetix's focus beyond oncology, adding Ocuvex's FDA-approved and late-stage ophthalmic treatments to its portfolio. Under the terms, Ocuvex shareholders would receive newly issued Onconetix stock and hold about 90% of the combined company.
Leadership from both firms expressed optimism, citing strategic growth and improved access to capital. The transaction remains subject to due diligence, regulatory approvals, financing and a final agreement. 
Onconetix meanwhile says there is no guarantee the merger will be finalized.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a>
<h2 class="wp-block-heading">How To Buy ONCO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Onconetix&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ONCO has a 52-week high of $21.40 and a 52-week low of $0.06.

ONCO

Why Onconetix (ONCO) Stock Is Exploding Higher

Nxu shares are trading higher after the company announced shareholders have approved the merger with Verde Bioresins.

SXTP

60 Degrees Pharmaceuticals shares are trading higher after the company announced a patent license agreement with Yale's School of Medicine and Public Health for the development and commercialization of Tafenoquine.

NAOV

NanoVibronix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 251.7%

OCUL

Ocular Therapeutics shares are trading higher after William Blair initiated coverage on the stock with an Outperform rating. Additionally, Needham reiterated a Buy rating

Onconetix shares are trading higher after the company signed a letter of intent contemplating a business combination with Ocuvex Therapeutics.

I admit it.
I hate K-1s.
For the uninitiated, K-1s are a tax form generated by a partnership to report income.
If you own Master Limited Partnerships, you get a K-1 instead of a 1099.
They can be a nightmare if you do your own taxes.
Pro Tip: If you own MLPs, do not do your own taxes.
Again, for those of you who have never owned them, Master Limited Partnerships are fantastic little dividend machines that allow you to own businesses that are formed as partnerships specifically for tax purposes.
I have owned many of them over the years, starting with cable TV partnerships in the 80s and 90s.
It seems like every time I stick a tax return in the mail or hit send to file, I would almost immediately get a corrected K-1, causing me to have to amend my return.
My accountants love K-1s.
I hate them.
However, I hate taxes even more, and owning oil and gas midstream MLPs allows me to earn fat yields and delay taxes.
MLPs are pass-through entities, which means they don&#8217;t pay corporate income tax. Instead, they &#8220;pass through&#8221; income, deductions, depreciation, and other tax goodies directly to you via a K-1. And while that sounds like a great deal—and it is—it comes with paperwork that could make your head spin like a slot machine.
The good news?
Most of what you get from an MLP isn&#8217;t actually taxable income. It&#8217;s classified as return of capital, thanks to heavy depreciation and amortization. That means you&#8217;re deferring taxes until you sell, when the IRS gets its cut as capital gains (and sometimes ordinary income via recapture).
You get paid now, and the tax man waits.
That&#8217;s the kind of relationship I can live with.
I know some people will avoid MLPs because they hate K-1s.
That&#8217;s unintelligent.
I love huge total returns a lot more than I hate K-1s.
Midstream MLPs (Energy Transfer, Plains All American) are the toll roads of the energy world. They transport oil and gas, and they make money whether oil is at $40 or $140.
Big, boring, and tax-efficient.
Most of the distribution is return of capital.
You are deferring taxes while collecting checks. If you&#8217;re a long-term, income-focused investor who doesn&#8217;t panic over paperwork (or has a good accountant), that&#8217;s a beautiful thing.
One of my favorite MLPs is Energy Transfer (Ticker: ET).
Energy Transfer is a large midstream MLP with a footprint across pipelines, terminals, natural gas liquids, and export facilities. This one is a cash cow.
It&#8217;s run by co-founder Kelcy Warren, a cowboy capitalist who may not win awards for governance but knows how to generate distributable cash flow like nobody&#8217;s business.
ET yields over 7%, covers the distribution by a mile, and has been deleveraging after some rocky years of debt-fueled expansion.
At today&#8217;s prices, you&#8217;re getting paid handsomely to wait while they keep buying back units and growing through bolt-on deals. It&#8217;s the kind of MLP you buy, hold, and use to fund your cigar and bourbon habit.
Just don&#8217;t hold these in an IRA unless you really know what you&#8217;re doing because UBTI (unrelated business taxable income) can turn your tax-sheltered account into a tax headache.
If you want to own high-yielding midstream assets in an IRA or other tax-deferred vehicle, consider owning closed-end funds that invest in MLPs.
If you love the income and tax deferral that MLPs offer but hate the K-1 paperwork more than a trip to the DMV, CEFs might be your ticket to the promised land.
When a closed-end fund buys MLPs, it does the dirty work for you. The fund itself files the K-1s with the IRS, handles all the accounting, and you, the shareholder, just get a 1099 at the end of the year. It&#8217;s like going from doing your own taxes in pen to using a concierge accountant—smooth, clean, and hassle-free.
The best choice for a closed-end fund right now is The Kayne Anderson Energy Infrastructure (Ticker: KYN) This closed-end fund primarily holds North American pipeline and storage companies. Top holdings include midstream favorites like Enterprise Products Partners (Ticker: EPD), Energy Transfer (Ticker: ET), and Williams Companies (Ticker: WMB). These are businesses that generate consistent cash flow through long-term contracts, largely insulated from commodity price swings. As of March 31, 2025, the fund reported net assets of $2.5 billion and a net asset value (NAV) per share of $14.64, reflecting a portfolio built around real, tangible assets.
What makes KYN particularly compelling today is the discount it trades at relative to its NAV, currently about 12%. That kind of pricing gives investors the chance to buy into high-quality infrastructure assets at a meaningful markdown.
In a market where many income plays have been bid up, this discount provides both a margin of safety and potential upside should the discount narrow over time. For those focused on long-term total return and patient capital, this is the kind of setup that quietly compounds in your favor.
KYN also continues to deliver reliable income. The fund recently declared a monthly distribution of $0.08 per share, which works out to an annual yield of just over 7% based on current market prices. Notably, approximately 60% of that payout is expected to be classified as return of capital, offering a tax-deferred stream of income that can enhance after-tax returns.

Opinion

Under the Radar: The Tax-Deferred Income Strategy Most Investors Overlook

Interactive Strength Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares are trading higher by 12.4% to $1.00 Tuesday morning after the company signed a <a href="https://www.benzinga.com/pressreleases/25/04/ac44681193/interactive-strength-inc-nasdaq-trnr-signs-binding-agreement-to-acquire-wattbike-a-15m-omni-chann">binding agreement</a> to acquire Wattbike, a UK-based indoor cycling brand. Interactive Strength says the deal strengthens the company&#8217;s position in the US, UK and German fitness markets, and will broaden its omni-channel portfolio with a focus on performance training, rehab and wellness.
Per the company, the acquisition is expected to close in the second quarter and be immediately accretive. Wattbike's CEO Stephen Loftus highlighted the opportunity for accelerated global growth, supported by TRNR's sales and marketing scale. 
TRNR also plans to integrate Wattbike with its Taiwan-based supply team and upcoming Sportstech acquisition, positioning the company as a uniquely diversified leader in global fitness.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a>
<h2 class="wp-block-heading">How To Buy TRNR Stock</h2>
By now you're likely curious about how to participate in the market for Interactive Strength &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Interactive Strength, which is trading at $0.89 as of publishing time, $100 would buy you 112.36 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TRNR has a 52-week high of $1,100.00 and a 52-week low of $0.80.

TRNR

What's Going On With Interactive Strength (TRNR) Stock?

HC Wainwright &amp; Co. analyst Edward White reiterates Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) with a Buy and maintains $15 price target.

HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target

RICK

RCI Hospitality shares are trading lower. The company reported Q2 revenue results.

Biotech

General

IGC Pharma Expands Phase 2 CALMA Trial With Site At Butler Hospital's Memory and Aging Program

PLAY

Dave & Buster's Entertainment shares are trading higher. The company reported Q4 financial results.

LUNR

Intuitive Machines shares are trading higher after the company announced it selected SpaceX's Falcon 9 rocket to launch its IM-4 mission.

Piper Sandler analyst Patrick Moley maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Overweight and raises the price target from $230 to $234.

CBOE

Piper Sandler Maintains Overweight on Cboe Global Markets, Raises Price Target to $234

Press Releases

NeuroOne® Regains Compliance with Nasdaq Listing Requirements

NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time

NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Health Care

NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace

NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Biomerica

BioSig Technologies

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

Daxor

electroCore

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

Femasys

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

NAYA Biosciences

Neuraxis

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Nexalin Technology

PAVmed

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Beyond Air

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies

Alliance Global Partners

Screenshot 2024-05-03 at 5.56.54 PM

Interview

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

Comments

NeuroOne Medical Tech

Interés en corto

NeuroOne Medical Tech (NASDAQ:NMTC) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL